Share：
Share this content in WeChat
X
[Chinese][PDF]61274
• Review •
Progress of Gd-EOB-DTPA in the diagnosis and evaluation of CRLM
HUANG Xiaolan  PENG Jie 

Cite this article as: Huang XL, Peng J. Progress of Gd-EOB-DTPA in the diagnosis and evaluation of CRLM[J]. Chin J Magn Reson Imaging, 2021, 12(10): 112-114, 124. DOI:10.12015/issn.1674-8034.2021.10.029.


[Abstract] Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) plays an important role in the diagnosis of colorectal liver metastasis (CRLM). It is highly accurate in the diagnosis of early CRLM and CRLM after chemotherapy, and provides a significant reference for the adjustment of CRLM treatment plan and the evaluation of curative effect after treatment. This paper describes the application progress of Gd-EOB-DTPA enhanced MRI in CRLM diagnosis and treatment.
[Keywords] Gd-EOB-DTPA；colorectal cancer；liver metastases；disappear；magnetic resonance imaging

HUANG Xiaolan   PENG Jie*  

Department of Radiology, the First Affiliated Hospital of Yangtze University, Jingzhou 434000, China

Peng J, E-mail: pengjie-77@163.com

Conflicts of interest   None.

Received  2021-05-11
Accepted  2021-06-28
DOI: 10.12015/issn.1674-8034.2021.10.029
Cite this article as: Huang XL, Peng J. Progress of Gd-EOB-DTPA in the diagnosis and evaluation of CRLM[J]. Chin J Magn Reson Imaging, 2021, 12(10): 112-114, 124. DOI:10.12015/issn.1674-8034.2021.10.029.

[1]
Lupinacci R, Penna C, Nordlinger B. Hepatectomy for resectable colorectal cancer metastases--indicators of prognosis, definition of resectability, techniques and outcomes[J]. Surg Oncol Clin N Am, 2007, 16(3): 493-506. DOI: 10.1016/j.soc.2007.04.014.
[2]
Manfredi S, Lepage C, Hatem C, et al. Epidemiology and management of liver metastases from colorectal cancer[J]. Ann Surg, 2006, 244(2): 254-259. DOI: 10.1097/01.sla.0000217629.94941.cf.
[3]
Choi Y, Huh J, Woo DC, et al. Use of gadoxetate disodium for functional MRI based on its unique molecular mechanism[J]. Br J Radiol, 2016, 89(1058): 20150666. DOI: 10.1259/bjr.20150666.
[4]
Vernuccio F, Gagliano DS, Cannella R, et al. Spectrum of liver lesions hyperintense on hepatobiliary phase: an approach by clinical setting[J]. Insights Imaging, 2021, 12(1): 8. DOI: 10.1186/s13244-020-00928-w.
[5]
Chernyak V, Fowler KJ, Heiken JP, et al. Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS)[J]. Magn Reson Imaging, 2019, 49(5): 1236-1252. DOI: 10.1002/jmri.26540.
[6]
Morsbach F, Sah BR, Spring L, et al. Perfusion CT best predicts outcome after radioembolization of liver metastases: a comparison of radionuclide and CT imaging techniques[J]. Eur Radiol, 2014, 24(7): 1455-1465. DOI: 10.1007/s00330-014-3180-3.
[7]
Vogl TJ, Pereira PL, Helmberger T, et al. Aktualisierte S3-Leitlinie zur Diagnostik und Therapie des kolorektalen Karzinoms: Bedeutung für die radiologische Diagnostik und Intervention [Updated S3 Guidelines-Diagnosis and Treatment of Colorectal Carcinoma: Relevance for Radiological Diagnosis and Intervention][J]. Rofo, 2019, 191(4): e2. DOI: 10.1055/a-0750-1762.
[8]
Zech CJ, Korpraphong P, Huppertz A, et al. Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases[J]. Br J Surg, 2014, 101(6): 613-621. DOI: 10.1002/bjs.9465.
[9]
Granata V, Fusco R, de Lutio di Castelguidone E, et al. Diagnostic performance of gadoxetic acid-enhanced liver MRI versus multidetector CT in the assessment of colorectal liver metastases compared to hepatic resection[J]. BMC Gastroenterol, 2019, 19(1): 129. DOI: 10.1186/s12876-019-1036-7.
[10]
Choi SH, Kim SY, Park SH, et al. Diagnostic performance of CT, gadoxetate disodium-enhanced MRI, and PET/CT for the diagnosis of colorectal liver metastasis: Systematic review and meta-analysis[J]. J Magn Reson Imaging, 2018, 47(5): 1237-1250. DOI: 10.1002/jmri.25852.
[11]
Vilgrain V, Esvan M, Ronot M, et al. A meta-analysis of diffusion-weighted and gadoxetic acid-enhanced MR imaging for the detection of liver metastases[J]. Eur Radiol, 2016, 26(12): 4595-4615. DOI: 10.1007/s00330-016-4250-5.
[12]
Malayeri AA, El Khouli RH, Zaheer A, et al. Principles and applications of diffusion-weighted imaging in cancer detection, staging, and treatment follow-up[J]. Radiographics, 201, 31(6): 1773-1791. DOI: 10.1148/rg.316115515.
[13]
Schulz A, Joelsen-Hatlehol ES, Brudvik KW, et al. Preoperative detection of colorectal liver metastases: DWI alone or combined with MDCT is no substitute for Gd-EOB-DTPA-enhanced MRI [J]. Acta Radiol, 2020, 61(3): 302-311. DOI: 10.1177/0284185119864000.
[14]
Vilgrain V, Esvan M, Ronot M, et al. A meta-analysis of diffusion-weighted and gadoxetic acid-enhanced MR imaging for the detection of liver metastases[J]. Eur Radiol, 2016, 26(12): 4595-4615. DOI: 10.1007/s00330-016-4250-5.
[15]
Stift J, Graf A, Schwarz C, et al. Microscopic biliary and perineural invasion and clinical outcome after neoadjuvant bevacizumab-based chemotherapy and liver resection in patients with colorectal liver metastases[J]. Eur J Surg Oncol, 2018, 44(1): 139-147. DOI: 10.1016/j.ejso.2017.11.018.
[16]
Okano K, Yamamoto J, Okabayashi T, et al. CT imaging of intrabiliary growth of colorectal liver metastases: a comparison of pathological findings of resected specimens[J]. Br J Radiol, 2002, 75(894): 497-501. DOI: 10.1259/bjr.75.894.750497.
[17]
Peungjesada S, Aloia TA, Kaur H, et al. Intrabiliary growth of colorectal liver metastasis: spectrum of imaging findings and implications for surgical management[J]. AJR Am J Roentgenol, 2013, 201(4): W582-W589. DOI: 10.2214/AJR.12.9508.
[18]
Reijonen P, Österlund P, Isoniemi H, et al. Histologically Verified Biliary Invasion was Associated with Impaired Liver Recurrence-Free Survival in Resected Colorectal Cancer Liver Metastases[J]. Scand J Surg, 2019, 108(3): 201-209. DOI: 10.1177/1457496918812237.
[19]
Nakai Y, Gonoi W, Kurokawa R, et al. MRI Findings of Liver Parenchyma Peripheral to Colorectal Liver Metastasis: A Potential Predictor of Long-term Prognosis. Radiology, 2020, 297(3): 584-594. DOI: 10.1148/radiol.2020202367.
[20]
Chinese Medical Doctor Association Surgeon Branch, Chinese Medical Association Surgery Branch Gastrointestinal Surgery Group, Chinese Medical Association Surgery Branch Colorectal Surgery Group, et al. China guideline for diagnosis and comprehensive treatment of colorectal liver metastases (2020 edition)[J]. J Clin Hepatol, 2021, 37(3): 543-553. DOI: 10.3969/j.issn.1001-5256.2021.03.009.
[21]
Stewart CL, Warner S, Ito K, et al. Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?[J]. Curr Probl Surg, 2018, 55(9): 330-379. DOI: 10.1067/j.cpsurg.2018.08.004.
[22]
Mao R, Zhao JJ, Bi XY, et al. A postoperative scoring system for post-hepatectomy early recurrence of colorectal liver metastases[J]. Oncotarget, 2017, 8(60): 102531-102539. DOI: 10.18632/oncotarget.20934.
[23]
Liu W, Sun Y, Zhang L, et al. Negative surgical margin improved long-term survival of colorectal cancer liver metastases after hepatic resection: a systematic review and meta-analysis[J]. Int J Colorectal Dis, 2015, 30(10): 1365-1373. DOI: 10.1007/s00384-015-2323-6.
[24]
Rahnemai-Azar AA, Cloyd JM, Weber SM, et al. Update on Liver Failure Following Hepatic Resection: Strategies for Prediction and Avoidance of Post-operative Liver Insufficiency[J]. J Clin Transl Hepatol, 2018, 6(1): 97-104. DOI: 10.14218/JCTH.2017.00060.
[25]
Qadan M, Garden OJ, Corvera CU, et al. Management of Postoperative Hepatic Failure[J]. J Am Coll Surg, 2016, 222(2): 195-208. DOI: 10.1016/j.jamcollsurg.2015.11.007.
[26]
Mai RY, Ye JZ, Bai T, et al.Advances in the prevention and treatment of posthepatectomy liver failure in patients with primary liver cancer[J]. J Clin Hepatol, 2018, 34(12): 2685-2692. DOI: 10.3969/j.issn.1001-5256.2018.12.039.
[27]
Levesque E, Martin E, Dudau D, et al. Current use and perspective of indocyanine green clearance in liver diseases[J]. Anaesth Crit Care Pain Med, 2016, 35(1): 49-57. DOI: 10.1016/j.accpm.2015.06.006.
[28]
Shen YH, Sun HC, Zhou J. Assessment of liver reserve function before hepatectomy[J/OL]. Chin J Hep Surg (Electronic Edition), 2019, 8(6): 469-472. DOI: 10.3877/cma.j.issn.2095-3232.2019.06.001.
[29]
Verde F, Romeo V, Maurea S. Advanced liver imaging using MR to predict outcomes in chronic liver disease: a shift from morphology to function liver assessment[J]. Quant Imaging Med Surg, 2020, 10(3): 805-807. DOI: 10.21037/qims.2020.02.03.
[30]
Costa AF, Tremblay St-Germain A, Abdolell M, et al. Can contrast-enhanced MRI with gadoxetic acid predict liver failure and other complications after major hepatic resection?[J]. Clin Radiol, 2017, 72(7): 598-605. DOI: 10.1016/j.crad.2017.02.004.
[31]
Ba-Ssalamah A, Bastati N, Wibmer A, et al. Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we?[J]. J Magn Reson Imaging, 2017, 45(3): 646-659. DOI: 10.1002/jmri.25518.
[32]
Bae KE, Kim SY, Lee SS, et al. Assessment of hepatic function with Gd-EOB-DTPA-enhanced hepatic MRI[J]. Dig Dis, 2012, 30(6): 617-622. DOI: 10.1159/000343092.
[33]
Yoshimura N, Saito K, Saguchi T, et al. Distinguishing hepatic hemangiomas from metastatic tumors using T1 mapping on gadoxetic-acid-enhanced MRI[J]. Magn Reson Imaging, 2013, 31(1):23-27. DOI: 10.1016/j.mri.2012.06.026.
[34]
Haimerl M, Schlabeck M, Verloh N, et al. Volume-assisted estimation of liver function based on Gd-EOB-DTPA-enhanced MR relaxometry[J]. Eur Radiol, 2016, 26(4): 1125-1133. DOI: 10.1007/s00330-015-3919-5
[35]
Yoon JH, Lee JM, Kim E, Okuaki T, et al. Quantitative Liver Function Analysis: Volumetric T1 Mapping with Fast Multisection B1 Inhomogeneity Correction in Hepatocyte-specific Contrast-enhanced Liver MR Imaging[J]. Radiology, 2017, 282(2): 408-417. DOI: 10.1148/radiol.2016152800.
[36]
Duan T, Jiang HY, Xia CC, et al. Assessing Liver Function in Liver Tumors Patients: The Performance of T1 Mapping and Residual Liver Volume on Gd-EOBDTPA-Enhanced MRI[J]. Front Med (Lausanne), 2020, 7: 215. DOI: 10.3389/fmed.2020.00215.
[37]
Khoo E, O'Neill S, Brown E, et al. Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases[J]. HPB (Oxford), 2016, 18(6): 485-493. DOI: 10.1016/j.hpb.2016.03.001.
[38]
Mitchell D, Puckett Y, Nguyen QN. Literature Review of Current Management of Colorectal Liver Metastasis[J]. Cureus, 2019, 11(1): e3940. DOI: 10.7759/cureus.3940.
[39]
Tsilimigras DI, Ntanasis-Stathopoulos I, Paredes AZ, et al. Disappearing liver metastases: A systematic review of the current evidence[J]. Surg Oncol, 2019, 29: 7-13. DOI: 10.1016/j.suronc.2019.02.005.
[40]
Pak LM, Gagnière J, Allen PJ, et al. Utility of Image Guidance in the Localization of Disappearing Colorectal Liver Metastases[J]. J Gastrointest Surg, 2019, 23(4): 760-767. DOI: 10.1007/s11605-019-04106-2.
[41]
Owen JW, Fowler KJ, Doyle MB, et al. Colorectal liver metastases: disappearing lesions in the era of Eovist hepatobiliary magnetic resonance imaging[J]. HPB (Oxford), 2016, 18(3): 296-303. DOI: 10.1016/j.hpb.2015.10.009.
[42]
Tani K, Shindoh J, Akamatsu N, et al. Management of disappearing lesions after chemotherapy for colorectal liver metastases: Relation between detectability and residual tumors[J]. J Surg Oncol, 2018, 117(2): 191-197. DOI: 10.1002/jso.24805.
[43]
Kepenekian V, Muller A, Valette PJ, et al. Evaluation of a strategy using pretherapeutic fiducial marker placement to avoid missing liver metastases[J]. BJS Open, 2019, 3(3): 344-353. DOI: 10.1002/bjs5.50140.
[44]
Koh DM, Ba-Ssalamah A, Brancatelli G, et al. Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging[J]. Eur Radiol, 2021, 31: 5615-5628. DOI: 10.1007/s00330-020-07637-4.
[45]
Park MJ, Hong N, Han K, et al. Use of Imaging to Predict Complete Response of Colorectal Liver Metastases after Chemotherapy: MR Imaging versus CT Imaging[J]. Radiology, 2017, 284(2): 423-431. DOI: 10.1148/radiol.2017161619.
[46]
Vujic J, Schöllnast H, Marsoner K, et al. Marking Disappearing Colorectal Liver Metastases After Complete Response to Neoadjuvant Chemotherapy via CT - A Pilot Study[J]. Anticancer Res, 2019, 39(7): 3847-3854. DOI: 10.21873/anticanres.13534.
[47]
Barimani D, Kauppila JH, Sturesson C, et al. Imaging in disappearing colorectal liver metastases and their accuracy: a systematic review[J]. World J Surg Oncol, 2020, 18(1): 264. DOI: 10.1186/s12957-020-02037-w.
[48]
Muaddi H, Silva S, Choi WJ, et al. When is a Ghost Really Gone? A Systematic Review and Meta-analysis of the Accuracy of Imaging Modalities to Predict Complete Pathological Response of Colorectal Cancer Liver Metastases After Chemotherapy[J]. Ann Surg Oncol, 2021, 28(10): 6805-6813. DOI: 10.1245/s10434-021-09824-z.

PREV Research progress of MRI in differentiating Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
NEXT The advance of magnetic resonance imaging in early acute intestinal ischemia
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn